TY - JOUR TI - A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Antimalarial Spiroindolone KAE609 (Cipargamin) To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers T2 - Antimicrobial Agents and Chemotherapy VL - 58 IS - 10 SP - 6209 EP - 6214 AU - Leong, F. Joel and Li, Ruobing and Jain, Jay Prakash and Lefèvre, Gilbert and Magnusson, Baldur and Diagana, Thierry T. and Pertel, Peter PB - American Society for Microbiology PY - 2014 PY - 2014 LA - English KW - Infectious Diseases KW - Pharmacology (medical) KW - Pharmacology SN - 0066-4804 SN - 1098-6596 UR - http://dx.doi.org/10.1128/aac.03393-14 UR - https://www.katalog.fh-zwickau.de/Record/ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTEyOC9hYWMuMDMzOTMtMTQ ER -